<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin ES</submitter><funding>National Science and Technology Council, Taiwan</funding><pagination>149</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9856072</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Dihydroorotase (DHOase) is the third enzyme in the pathway used for the biosynthesis of pyrimidine nucleotides. In mammals, DHOase is active in a trifunctional enzyme, CAD, which also carries out the activities of carbamoyl phosphate synthetase and aspartate transcarbamoylase. Prior to this study, it was unknown whether the FDA-approved clinical drug 5-fluorouracil (5-FU), which is used as an anticancer therapy, could bind to the DHOase domain of human CAD (huDHOase). Here, we identified huDHOase as a new 5-FU binding protein, thereby extending the 5-FU interactome to this human enzyme. In order to investigate where 5-FU binds to huDHOase, we solved the complexed crystal structure at 1.97 Å (PDB ID 8GVZ). The structure of huDHOase complexed with malate was also determined for the sake of c</pubmed_abstract><journal>Biomolecules</journal><pubmed_title>Complexed Crystal Structure of the Dihydroorotase Domain of Human CAD Protein with the Anticancer Drug 5-Fluorouracil.</pubmed_title><pmcid>PMC9856072</pmcid><funding_grant_id>NSTC 111-2622-E-025-002</funding_grant_id><pubmed_authors>Huang YH</pubmed_authors><pubmed_authors>Lin ES</pubmed_authors><pubmed_authors>Peng WF</pubmed_authors><pubmed_authors>Huang CY</pubmed_authors><pubmed_authors>Yang PC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Complexed Crystal Structure of the Dihydroorotase Domain of Human CAD Protein with the Anticancer Drug 5-Fluorouracil.</name><description>Dihydroorotase (DHOase) is the third enzyme in the pathway used for the biosynthesis of pyrimidine nucleotides. In mammals, DHOase is active in a trifunctional enzyme, CAD, which also carries out the activities of carbamoyl phosphate synthetase and aspartate transcarbamoylase. Prior to this study, it was unknown whether the FDA-approved clinical drug 5-fluorouracil (5-FU), which is used as an anticancer therapy, could bind to the DHOase domain of human CAD (huDHOase). Here, we identified huDHOase as a new 5-FU binding protein, thereby extending the 5-FU interactome to this human enzyme. In order to investigate where 5-FU binds to huDHOase, we solved the complexed crystal structure at 1.97 Å (PDB ID 8GVZ). The structure of huDHOase complexed with malate was also determined for the sake of c</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-04T10:21:25.566Z</modification><creation>2025-02-19T00:12:52.069Z</creation></dates><accession>S-EPMC9856072</accession><cross_references><pubmed>36671534</pubmed><doi>10.3390/biom13010149</doi></cross_references></HashMap>